The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kolyadina I.V.

Russian Medical Academy of Continuing Professional Education, Moscow, Russia

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

Poddubnaia I.V.

Kafedra onkologii RMAPO, Moskva

Role of biological heterogeneity in recurrent and metastatic breast cancer

Authors:

Kolyadina I.V., Andreeva Yu.Yu., Frank G.A., Poddubnaia I.V.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2018;80(6): 62‑67

DOI: 10.17116/patol20188006162

Read: 8687 times

Download PDF (RU)
Contact the author
Table of contents

ROLE OF BIOLOGICAL HETEROGENEITY IN RECURRENT AND METASTATIC BREAST CANCER
ROLE OF BIOLOGICAL HETEROGENEITY IN RECURRENT AND METASTATIC BREAST CANCER

To cite this article:

Kolyadina IV, Andreeva YuYu, Frank GA, Poddubnaia IV. Role of biological heterogeneity in recurrent and metastatic breast cancer. Russian Journal of Archive of Pathology. 2018;80(6):62‑67. (In Russ.)
https://doi.org/10.17116/patol20188006162

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Possibilities of drug treatment for pseudomyxoma peri­tonei of appe­ndiceal origin. P.A. Herzen Journal of Onco­logy. 2025;(6):59-64
Endo­thelial function in patients with heart failure with preserved ejection fraction unde­rgoing multicomponent drug therapy. Russian Cardiology Bulletin. 2025;(4-2):135-144
Abstract:

Breast cancer (BC) is a heterogeneous tumor, the biological characteristics of which vary with its growth and progression. Information on key tumor receptors (ER, PR, HER2, and Ki-67) is the basis for individualizing the diagnostic and treatment algorithm at all BC stages; however, the feasibility of biopsy of distant metastases and the re-testing of the biological subtype of BC in its suspected progression are being actively discussed in clinical practice. This review presents an update on the features of metastasis in different biological BC subtypes and assesses the clinical and prognostic role of biopsy of distant metastases in the lung, bones, liver, and brain. It shows the frequency of discordance in receptor status between primary and recurrent tumors at different sites of metastases, as well as the impact of changes in receptor status on survival rates in different biological BC subtypes. The relevance of performing biopsies in BC progression is shown to be beyond question, because it makes it possible to confirm the fact that the disease progresses, to re-test the biological subtype of recurrent BC, and to find new targets that allow the most effective drug treatment regimens to be used.

Keywords:

recurrent and metastatic breast cancer
heterogeneity of breast cancer
discordance in receptor status of tumor
features of metastasis in different biological breast cancer subtypes
drug therapy
personalized approach to breast cancer therapy

Authors:

Kolyadina I.V.

Russian Medical Academy of Continuing Professional Education, Moscow, Russia

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

Poddubnaia I.V.

Kafedra onkologii RMAPO, Moskva

Close metadata

References:

  1. GLOBOCAN 2012. Available at: https://globocan.iarc.fr/Default.aspx
  2. Kaprin AD, Starinskii VV, Petrova GV, eds. Zlokachestvennye novoobrazovaniya v Rossii v 2016 (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2018. (In Russ.) Available at: https://www.oncology.ru/service/statistics/malignant_tumors/2016.pdf
  3. Zhang Y, Schroeder BE, Jerevall PL, Ly A, Nolan H, Schnabel CA, Sgroi DC. A novel breast cancer index for prediction of distant recurrence in HR+ early-stage breast cancer with One to three positive nodes. Clin Cancer Res. 2017;23(23):7217-7224. https://doi.org/10.1158/1078-0432.CCR-17-1688
  4. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-1846. https://doi.org/10.1056/NEJMoa1701830
  5. Kolyadina IV, Poddubnaya I, Pavlikova O, Komov D, Andreeva Yu, Frank G. Features of p53 expression in residual tumors in Russian women after neoadjuvant chemotherapy of breast cancer stage T1-3N0-1. J Clin Oncol. 2017;35(15,Suppl.):e12121. https://doi.org/10.1200/JCO.2017.35.15_suppl.e12121
  6. Kolyadina IV, Poddubnaya I, Van De Velde CJH, Kuppen PJK, Bastiaannet E, Davydov M, Kotov D, Frank G. The prognostic value of the immune profile of breast cancer stage I in Russian and Dutch women. J Clin Oncol. 2016;34(15:Suppl.):e23108. https://doi.org/10.1200/JCO.2016.34.15_suppl.e23108
  7. Moskvina LV, Andreeva YuYu, Zavalishina LE, Ilatovskaya M, Frank G. Breast cancer intratumoral heterogeneity in routine practice. Virchows Archiv. 2016;469(Suppl.1):S56. https://www.springer.com/medicine/pathology/journal/428
  8. Kolyadina IV, Poddubnaya IV, Frank GA, Komov DV, Karseladze AI, Ermilova VD, Vishnevskaya YV. Stage I breast cancer heterogeneity: biological and predictive value. Malignant Tumors. 2015;1:31-40.
  9. Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, Wei W, Zhang Y, Sun S. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8(17):27990-27996. https://doi.org/10.18632/oncotarget.15856
  10. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, Bahoric B, Sultanem K, Muanza T. Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus. 2016;8(12):e924. https://doi.org/10.7759/cureus.924
  11. Kaplan M, Arslan U, Isıkdogan A, Dane F, Oksuzoglu B, Inanc M, et al. Biological subtypes and distant relapse patern in breast cancer paients afer curaive surgery. Study of Anatolian Society of Medical Oncology. Breast Care (Basel). 2016;11(4):248-252. https://doi.org/10.1056/NEJMoa1701830
  12. Qu Q, Zong Y, Fei XC, Chen XS, Xu C, Lou GY, Shen KW. The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. World J Surg Oncol. 2014;12:93. https://doi.org/10.1186/1477-7819-12-93
  13. Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013;24(1):101-108. https://doi.org/10.1093/annonc/mds248
  14. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA; Breast Recurrence in Tissues Study Group. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010;12(6):R92. https://doi.org/10.1186/bcr2771
  15. Erdem GU, Altundag K, Ozdemir NY, Sahin S, Demirci NS, Karatas F, Bozkaya Y, Aytekin A, Tasdemir V, Aslan AC, Sever AR, Zengin N. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer. J BUON. 2017;22(2):365-376.
  16. Lower EE, Khan S, Kennedy D, Baughman RP. Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer (Dove Med Press). 2017;9:515-520. https://doi.org/10.2147/BCTT.S137709
  17. Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601-2608. https://doi.org/10.1200/JCO.2011.37.2482
  18. Shin HC, Han W, Moon HG, Im SA, Moon WK, Park IA, Park SJ, Noh DY. Discordant ER, PR, and HER2 status between primary and metastatic breast cancer as prognostic factor. J Clin Oncol. 2013;31(15,Suppl.):abstr.1039. https://doi.org/10.1200/jco.2013.31.15_suppl.1039
  19. Ilgun S, Sarsenov D, Erdogan Z, Ordu C, Celebi F, Nur Pilanci K, Ozturk A, Selamoglu D, Alco G, Aktepe F, Eralp Y, Tuzlali S, Ozmen V. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients. J BUON. 2016;21(6):1425-1432.
  20. Shachar SS, Mashiach T, Fried G, Drumea K, Shafran N, Muss HB, Bar-Sela G. Biopsy of breast cancer metastases: patient characteristics and survival. BMC Cancer. 2017;17(1):7. https://doi.org/10.1186/s12885-016-3014-6
  21. Gupta S, Wallace MJ, Cardella JF, Kundu S, Miller DL, Rose SC; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for percutaneous needle biopsy. J Vasc Interv Radiol. 2010;21(7):969-975.
  22. Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol. 2013;52(8):1649-1656. https://doi.org/10.3109:0284186X.2012.754990
  23. Matsuura K, Itamoto T, Noma M, Ohara M, Akimoto E, Doi M, Nishisaka T, Arihiro K, Kadoya T, Okada M. Signifcance of lung biopsy for the defniive diagnosis of lung nodules in breast cancer paients. Mol Clin Oncol. 2018;8(2):250-256. https://doi.org/10.3892:mco.2017.1511
  24. Liu J, Deng H, Jia W, Zeng Y, Rao N, Li S, Jin L, Wu J, Song E, Su F. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment. J Cancer Res Clin Oncol. 2012;138(5):837-842.
  25. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol. 2011;22(10):2227-2233. https://doi.org/10.1093:annonc:mdq751
  26. Botteri E, Disalvatore D, Curigliano G, Brollo J, Bagnardi V, Viale G, Orsi F, Goldhirsch A, Rotmensz N. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast. 2012;21(3):284-288. https://doi.org/10.1016/j.breast.2011.12.014
  27. Timmer M, Werner JM, Röhn G, Ortmann M, Blau T, Cramer C, Stavrinou P, Krischek B, Mallman P, Goldbrunner R. Discordance and conversion rates of progesterone-, estrogen-, and HER2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy. Anticancer Res. 2017;37(9):4859-4865.
  28. Jung J, Lee SH, Park M, Youn JH, Shin SH, Gwak HS, Yoo H. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. J Neurooncol. 2018;137(2):295-302. https://doi.org/10.1007/s11060-017-2717-0
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.